Literature DB >> 13725919

Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole.

H J EGGERS, I TAMM.   

Abstract

2-(alpha-Hydroxybenzyl)-benzimidazole (HBB) inhibited the cytopathic effects of the following enteroviruses: polio 1 to 3; Coxsackie A9; Coxsackie B 1 to 6; and ECHO virus types 1 to 9, 11 to 21, and 24 to 27. The following enteroviruses were not inhibited: Coxsackie A types 7, 11, 13, 16, and 18; and ECHO types 22, 23, and 28. Other HBB-insusceptible viruses were: arbor B and C, reo 1 to 3; adeno 2 to 4; influenza B; para-influenza 2 and 3; mumps; herpes simplex, and vaccinia. HBB had no inactivating effect on viral infectivity, but rather inhibited some intracellular step in the reproductive cycle of susceptible viruses. With all viruses examined, inhibition of viral cytopathic effects appeared to be due to inhibition of virus multiplication. Virus inhibition by HBB was demonstrable in monkey kidney, HeLa, and ERK cells. HBB-susceptible viruses varied quantitatively in their susceptibility to the compound, and different strains of the same virus also exhibited varying susceptibility. No relationship was found between attenuation of polioviruses and their susceptibility to the compound. After passage of HBB-susceptible enteroviruses in the presence of the compound, virus populations with lowered susceptibility to HBB were obtained. At virus inhibitory concentrations, HBB did not affect the morphology of cells, nor the following cellular metabolic activities: oxygen uptake; glucose utilization; lactic acid production; and incorporation of adenosine into RNA, and of alanine into proteins. The rates of multiplication of HeLa and ERK. cells were not significantly altered by HBB at virus inhibitory concentrations.

Entities:  

Keywords:  IMIDAZOLES/pharmacology; VIRUSES/pharmacology

Mesh:

Substances:

Year:  1961        PMID: 13725919      PMCID: PMC2137377          DOI: 10.1084/jem.113.4.657

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Amino acid metabolism in mammalian cell cultures.

Authors:  H EAGLE
Journal:  Science       Date:  1959-08-21       Impact factor: 47.728

2.  Classification of the "2060" virus as ECHO 28 and further study of its properties.

Authors:  W PELON
Journal:  Am J Hyg       Date:  1961-01

3.  Assessment of correlation between certain in vitro poliovirus markers and monkey neurovirulence.

Authors:  V J CABASSO; E L JUNGHERR; S LEVINE; A W MOYER; M ROCA-GARCIA; H R COX
Journal:  Br Med J       Date:  1960-07-16

4.  Multiplication of vaccinia virus in the chorioallantoic membrane in vitro.

Authors:  J R OVERMAN; I TAMM
Journal:  Virology       Date:  1957-02       Impact factor: 3.616

5.  Coxsackie A7 virus and the Russian poliovirus Type 4.

Authors:  K HABEL; L N LOOMIS
Journal:  Proc Soc Exp Biol Med       Date:  1957-07

6.  Effects of certain purines and related compounds on virus propagation.

Authors:  A C HOLLINSHEAD; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

7.  The determination of lacic acid in microgram quantities.

Authors:  R P HULLIN; R L NOBLE
Journal:  Biochem J       Date:  1953-09       Impact factor: 3.857

8.  Relation of oxygen and temperature in the preservation of tissues by refrigeration.

Authors:  J H HANKS; R E WALLACE
Journal:  Proc Soc Exp Biol Med       Date:  1949-06

9.  The inactivation of enterovirus infectivity by the sulfhydryl reagent p-chloromercuribenzoate.

Authors:  P W CHOPPIN; L PHILIPSON
Journal:  J Exp Med       Date:  1961-04-01       Impact factor: 14.307

10.  Relationship between structure of benzimidazole derivatives and selective virus inhibitory activity. Inhibition of poliovirus multiplication and cytopathic effects by 2-(alpha-hydroxybenzyl)-benzimidazole, and its 5-chloroderivative.

Authors:  I TAMM; R BABLANIAN; M M NEMES; C H SHUNK; F M ROBINSON; K FOLKERS
Journal:  J Exp Med       Date:  1961-04-01       Impact factor: 14.307

View more
  36 in total

1.  THE DRUG-REQUIRING PHASE IN THE GROWTH OF DRUG-DEPENDENT ENTEROVIRUSES.

Authors:  H J EGGERS; E REICH; I TAMM
Journal:  Proc Natl Acad Sci U S A       Date:  1963-08       Impact factor: 11.205

2.  CHARACTERS OF GUANIDINE RESISTANT MUTANTS OF TYPE 1 POLIOVIRUS.

Authors:  F HORODNICEANU; D SERGIESCU; R KLEIN; M ZAMFIRESCU; A A COMBIESCU
Journal:  Arch Gesamte Virusforsch       Date:  1964

3.  RESCUE OF DRUG-REQUIRING AND DRUG-INHIBITED ENTEROVIRUSES.

Authors:  N IKEGAMI; H J EGGERS; I TAMM
Journal:  Proc Natl Acad Sci U S A       Date:  1964-12       Impact factor: 11.205

4.  Poliovirus-induced RNA polymerase and the effects of virus-specific inhibitors on its production.

Authors:  D BALTIMORE; H J EGGERS; R M FRANKLIN; I TAMM
Journal:  Proc Natl Acad Sci U S A       Date:  1963-06       Impact factor: 11.205

5.  [Selective inhibition of propagation of enteroviruses by 2-(a-hydroxy-benzyl)-benzimidazole].

Authors:  H J EGGERS; I TAMM
Journal:  Z Hyg Infektionskr       Date:  1961

Review 6.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

7.  Studies on the 2060-JH viruses. II. Seroepidemiological survey of infections with the 2060 agent in a group of families.

Authors:  G W RAKE; R SHARMA; G H WERNER
Journal:  Arch Gesamte Virusforsch       Date:  1962

8.  Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group.

Authors:  G Stanway; N Kalkkinen; M Roivainen; F Ghazi; M Khan; M Smyth; O Meurman; T Hyypiä
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Evaluation of bis-benzimidazoles in the treatment of murine lymphocytic choriomeningitis virus infections.

Authors:  J P Stella; J Michaelson; S L Dorfman; J H Morgan; C J Pfau
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

10.  A distinct picornavirus group identified by sequence analysis.

Authors:  T Hyypiä; C Horsnell; M Maaronen; M Khan; N Kalkkinen; P Auvinen; L Kinnunen; G Stanway
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.